ArticleFrontiers in immunology2019

Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.

Markus J Harder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.